As the Markets Waver, Here’s What We’ve Been Watching
zPremium - Greece unknowns weigh on the market going into the holiday weekend (Happy fourth by the way!), but the referendum on Sunday should offer some perspective … Continue Reading
PremiumSearch Results for gene therapy
Poop Pills Worth $2 Billion in Latest Biotech IPO. Yep, Poop Pills
Insights - That’s a bit disingenuous, but Seres Health’s (MCRB) SER-109 isn’t far from it. The company made a splash on Friday when it IPO’d at $18, and … Continue Reading
Read now
You Don’t See That Very Often – Drug Developer May Close up Shop Entirely
Insights - It’s one of the most elusive events in biotech: the liquidation. But after a trial failure of epic proportions – and a collapse in its stock … Continue Reading
Read now
Biotech Stocks Surged Through a Key Level this Week
Insights - Disparate results from two gene therapy developers are worth a mention in this week’s biotech recap. Avalanche Biotechnologies (AAVL) blew up spectacularly this Monday with … Continue Reading
Read now
Biotech Finally Breaks Through the Wall
Research - Biotech is finally breaking out to new all-time highs, and you’ll be hard-pressed to find much red on your watch-list. We wrote about the current … Continue Reading
Read now
Takeaways From bluebird’s Latest Presentation
Research - This weekend, bluebird bio (BLUE) and investigators presented much-awaited data for the first Sickle Cell Disease (SCD) patient treated with LentiGlobin (BB305) in the HBG-205 … Continue Reading
Read nowStocks had a Fine Finish to a Rough Week
Recap - After a mostly red week, stocks gapped higher Friday morning with the latest jobs report. The jobless rate fell to 5.4%, the lowest since 2008, and a … Continue Reading
Read now